| 25.15 0.35 (1.41%) | 11-11 15:58 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 34.48  |
1-year : | 39.3 |
| Resists | First : | 29.52 |
Second : | 33.65 |
| Pivot price | 28.97 |
|||
| Supports | First : | 22.86 | Second : | 19.01 |
| MAs | MA(5) : | 25.88 |
MA(20) : | 29.61 |
| MA(100) : | 31.04 |
MA(250) : | 0 | |
| MACD | MACD : | -1.6 |
Signal : | -1 |
| %K %D | K(14,3) : | 22.7 |
D(3) : | 17.7 |
| RSI | RSI(14): 34.7 |
|||
| 52-week | High : | 42.5 | Low : | 22.86 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CAI ] has closed above bottom band by 11.4%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 26.22 - 26.35 | 26.35 - 26.48 |
| Low: | 23.84 - 24 | 24 - 24.15 |
| Close: | 24.51 - 24.76 | 24.76 - 25 |
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and machine learning algorithms. The company's molecular profiling services portfolio includes MI Profile, a tissue-based molecular profiling solution; and Caris Assure, a blood-based molecular profiling solution for cancer treatment. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company was founded in 2008 and is headquartered in Irving, Texas.
Mon, 10 Nov 2025
Top Executive Makes Bold Move with Major Stock Purchase in Caris Life Sciences! - TipRanks
Mon, 10 Nov 2025
Spetzler buys Caris Life Sciences (CAI) shares worth $9,540 - Investing.com India
Sun, 09 Nov 2025
Caris Life Sciences: Assessing Valuation After Strong Q3 Profit Swing and Raised 2025 Revenue Outlook - simplywall.st
Sat, 08 Nov 2025
Why Caris Life Sciences (CAI) Raised Revenue Outlook and Tightened Governance After Record Quarterly Profit - Sahm
Thu, 06 Nov 2025
Caris Life Sciences Reports Record Revenue Growth - The Globe and Mail
Thu, 06 Nov 2025
Decoding Caris Life Sciences Inc (CAI): A Strategic SWOT Insight - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 281 (M) |
| Shares Float | 92 (M) |
| Held by Insiders | 48.6 (%) |
| Held by Institutions | 46 (%) |
| Shares Short | 3,730 (K) |
| Shares Short P.Month | 1,900 (K) |
| EPS | -3.95 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.61 |
| Profit Margin | -52.3 % |
| Operating Margin | -10 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 81.3 % |
| Gross Profit (p.s.) | 1.02 |
| Sales Per Share | 1.89 |
| EBITDA (p.s.) | -0.51 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -132 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -6.4 |
| PEG Ratio | 0 |
| Price to Book value | 15.63 |
| Price to Sales | 13.26 |
| Price to Cash Flow | -53.5 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|